Reliant Will Launch Pronova's Omacor In 2005
This article was originally published in The Pink Sheet Daily
Executive Summary
Reliant will maintain the NDA for Omacor (omega-3 acid ethyl esters) and its sales force will be the sole U.S. marketer of the hypertriglyceridemia treatment. Abbott's Ross Products division filed the original NDA, as well as a separate application FDA has deemed "approvable."